Conference
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.
Authors
Siu LL; Italiano A; Miller WH; Blay J-Y; Gietema JA; Bang Y-J; Mileshkin LR; Hirte HW; Reckner M; Higgins B
Volume
32
Pagination
pp. 2535-2535
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.2535
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X